Engaged in advancing innovative solutions for large-scale market applications
Medigus commenced trading of its American Depositary Shares (ADSs) represented by American Depositary Receipts (ADRs) through The Bank of New York Mellon, on May 20, 2015 under “MDGS”. Each ADR represents 100 ordinary shares of the Company. Ordinary shares also trade on the Tel Aviv Stock Exchange under the symbol “MDGS.”
You should contact your broker or the company’s depositary bank, BNY Mellon: Arlene C. Villareal, Vice President BNY Mellon, Depositary Receipts Division Global Client Solutions Tel: 212-815-8162 or [email protected]
You can download or request hard copies of Medigus’ annual reports and SEC filings. http://www.sec.gov/cgi-bin/browse-edgar?company=medigus&owner=exclude&action=getcompany.
Management is headquartered in California and Israel. Medigus has sales offices in California and Israel and R&D center in Omer, Israel
Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions, such as our proprietary endoscopic device, the MUSE system, designed to treat gastroesophageal reflux disease (GERD).